Obstructive Sleep Apnea

Definition And Core Concepts

• Obstructive sleep apnea belongs to a broader spectrum of sleep-disordered breathing.
• It is characterized by repeated episodes of prolonged upper airway obstruction occurring during sleep.
• These episodes occur despite continued or increased respiratory effort by the patient.
• Obstruction results in either a complete cessation of airflow (apnea) or a partial cessation (hypopnea).
• Primary snoring differs as it lacks associated ventilatory abnormalities like hypoxemia or hypercapnia on polysomnography.
• Primary snoring may still associate with subtle breathing abnormalities and adverse neurodevelopmental outcomes.

Criteria

• Apnea: A cessation of airflow lasting $\ge 10$ seconds (or $\ge 2$ missed breaths in pediatric populations).
• Hypopnea: A reduction in airflow ($\ge 30\mathrm{\%}$) accompanied by an oxygen desaturation (typically $\ge 3\mathrm{\%}$ or $\ge 4\mathrm{\%}$) or an arousal.
• AHI (Apnea-Hypopnea Index): The average number of these events per hour of sleep.
  • Adults: $\ge 5$ events/hour with symptoms (or $\ge 15$ events/hour asymptomatic).
  • Pediatrics: $\ge 1$ event/hour is often considered abnormal.

Pathophysiology

• Obstructive sleep apnea upregulates systemic inflammatory pathways.
• This upregulation increases C-reactive protein and various interleukins.
• Systemic inflammation links directly to metabolic dysfunction, promoting insulin resistance and dyslipidemia.
• The condition induces alterations in neurohormones such as leptin.
• Increased sympathetic nervous system activity and inflammation alter the vascular endothelium.
• These vascular changes elevate systemic blood pressure and contribute to ventricular dysfunction.
• Cognitive impairment results from repeated arousals that cause significant sleep fragmentation and daytime sleepiness.
• Intermittent hypoxia leads to inflammatory vascular changes within the brain.

Etiology And Risk Factors

• The disorder is caused by an anatomically or functionally narrowed upper airway.
• Pathogenesis involves decreased upper airway patency and increased upper airway collapsibility.
• Reduced pharyngeal muscle tone heavily contributes to airway collapsibility.
• A decreased central ventilatory drive to breathe against the obstruction worsens the condition.

High-Risk Groups

• Adenotonsillar hypertrophy represents the most frequent cause of upper airway obstruction.
• Obesity significantly increases airway resistance due to excess adipose tissue in the throat, neck, and chest wall.
• Obese children harbor a higher risk for postoperative complications and residual disease following adenotonsillectomy.
• Down syndrome patients possess a prevalence reaching up to 70%.
• This high prevalence in Down syndrome stems from facial anatomy, hypotonia, macroglossia, central adiposity, and concurrent hypothyroidism.
• Neuromuscular diseases, such as hypotonic cerebral palsy, increase airway collapsibility.
• Arnold-Chiari malformation and thalamic dysregulation decrease central respiratory drive.

Anatomical Predisposing Factors

Epidemiology

• The prevalence documented by overnight sleep studies rests between 1% and 4% in the pediatric population.
• Parent-reported habitual snoring occurs in approximately 8% of all children.
• The peak age of incidence occurs between 2 and 8 years.
• The condition is more common in males, particularly following puberty.
• African American and Asian children demonstrate an increased disease prevalence.
• A history of prematurity and a positive family history act as significant risk factors.

Clinical Manifestations

Nocturnal Symptoms

• Patients exhibit loud, frequent, and highly disruptive snoring.
• Parents often observe breathing pauses, choking episodes, or gasping during sleep.
• Sleep is distinctly restless and accompanied by nocturnal diaphoresis.
• Children adopt unusual sleeping positions, frequently hyperextending the neck.
• Secondary enuresis and parasomnias, including sleepwalking and sleep terrors, occur frequently.

Daytime And Neurobehavioral Symptoms

• Daytime symptoms include chronic mouth breathing, dry mouth, and hyponasal speech.
• Children may complain of morning headaches and difficulty swallowing.
• Poor appetite can occasionally lead to severe failure to thrive.
• Daytime sleepiness manifests as difficulty waking in the morning and frequent napping.
• Mood changes feature irritability, emotional dysregulation, and low frustration tolerance.
• Behavioral issues include hyperactivity, impulsivity, and oppositional behavior.
• These neurobehavioral symptoms show substantial diagnostic overlap with Attention Deficit Hyperactivity Disorder (ADHD).

Diagnostic Evaluation

Clinical Assessment

• Physical examination findings suggest the diagnosis but are not pathognomonic.
• Growth assessment may reveal severe obesity or paradoxical failure to thrive.
• Nasal evaluation shows "allergic shiners" and obligatory mouth breathing.
• Oropharyngeal examination identifies enlarged tonsils and a narrowed posterior pharyngeal space.
• Craniofacial assessment may reveal adenoidal facies, characterized by an open mouth posture and a long face.
• Cardiovascular examination must assess for systemic hypertension, pulmonary hypertension, or cor pulmonale in severe cases.

Polysomnography (Gold Standard)

• An in-lab, technician-supervised, overnight polysomnogram remains the gold standard diagnostic tool.
• It differentiates obstructive sleep apnea from primary snoring accurately.
• Sleep staging utilizes electroencephalography, electrooculography, and chin/leg electromyography.
• Respiration is monitored via oronasal thermal sensors, nasal pressure transducers, and chest/abdominal bands.
• Gas exchange is evaluated using pulse oximetry and end-tidal or transcutaneous carbon dioxide monitors.
• The Apnea-Hypopnea Index (AHI) represents the total number of apneas and hypopneas per hour of sleep.
• In children $\le 12$ years, an obstructive AHI > 1 event/hour or a total AHI > 1.5 events/hour confirms the diagnosis.
• In adolescents, an AHI $\ge 5$ events/hour is utilized as the diagnostic cutoff.
• A pediatric AHI between 1 and 5 represents mild disease, 5 to 10 indicates moderate disease, and >10 signifies severe disease.

Alternative Diagnostic Modalities

• Alternative tests are considered when in-lab polysomnography remains unavailable.
• Options include nocturnal video recording and nocturnal oximetry.
• Daytime nap polysomnography and ambulatory home polysomnography may also be utilized.

Management Strategies

American Academy Of Pediatrics Guidelines

Specific Interventions

• Adenotonsillectomy yields complete resolution in 70% to 90% of uncomplicated cases.
• Drug-induced sleep endoscopy helps identify alternative sites of obstruction in cases of residual disease.
• Continuous Positive Airway Pressure (CPAP) or BiPAP acts as the primary non-surgical treatment.
• Positive airway pressure is indicated for residual postoperative disease or when surgery is contraindicated due to severe obesity or hypotonia.
• Strict weight loss protocols are crucial for all overweight and obese patients.
• Intranasal corticosteroids and leukotriene inhibitors help manage mild disease by effectively reducing airway inflammation.
• Aggressive medical treatment of concurrent allergies and gastroesophageal reflux is strictly recommended.
• Oral appliances, such as mandibular advancing devices and palatal expanders, benefit select cases following orthodontic consultation.
• Myofunctional therapy provides targeted exercises to re-pattern oral and facial musculature.
• Hypoglossal nerve stimulation acts as a novel surgical treatment showing promise in select pediatric cases, particularly Down syndrome.